Axovant Gene Therapies Ltd. (AXGT) financial statements (2020 and earlier)

Company profile

Business Address 11-12 ST. JAMES'S SQUARE
LONDON, SW1Y 4LB
State of Incorp.
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28107154213276
Cash and cash equivalents28107154213276
Receivables22211
Other undisclosed current assets46265
Total current assets:33115158220282
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment11300
Other noncurrent assets01   
Other undisclosed noncurrent assets66 30
Total noncurrent assets:98330
TOTAL ASSETS:42123161223282
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities212236439
Accounts payable02491
Accrued liabilities202132358
Debt102110  
Due to related parties  132
Other undisclosed current liabilities    5
Total current liabilities:3143474616
Noncurrent Liabilities
Long-term debt and lease obligation7234351 
Long-term debt, excluding current maturities6234351 
Operating lease, liability0
Total noncurrent liabilities:7234351 
Total liabilities:3766909816
Stockholders' equity
Stockholders' equity attributable to parent55671125267
Common stock  000
Additional paid in capital747741628460421
Accumulated other comprehensive income0100 
Accumulated deficit(742)(686)(557)(335)(154)
Total stockholders' equity:55671125267
TOTAL LIABILITIES AND EQUITY:42123161223282

Income statement (P&L) ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
Operating expenses(66)(127)(213)(180)(133)
Other undisclosed operating income (loss)1(2)(7)(2) 
Operating loss:(65)(129)(221)(182)(133)
Interest and debt expense(6)(8)(8)(1) 
Loss from continuing operations before equity method investments, income taxes:(71)(136)(228)(183)(133)
Other undisclosed income from continuing operations before income taxes8881 
Loss from continuing operations before income taxes:(63)(129)(221)(182)(133)
Income tax expense (benefit)(0)(0)(1)10
Net loss:(63)(129)(222)(181)(133)
Other undisclosed net loss attributable to parent(2)    
Net loss available to common stockholders, diluted:(65)(129)(222)(181)(133)

Comprehensive Income ($ in millions)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
Net loss:(63)(129)(222)(181)(133)
Comprehensive loss:(63)(129)(222)(181)(133)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2)1(0)0 
Comprehensive loss, net of tax, attributable to parent:(65)(128)(222)(181)(133)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: